ADVERTISEMENT
You do not have any notes added to this page yet
Introduction
Demographics
Causes
Clinical features
Variation in skin types
Complications
Diagnosis
Differential diagnoses
Treatment
Prevention
Outcome
Acral lentiginous melanoma (ALM) is a rare subtype of melanoma arising on the palms, soles, or under the nails. It is also known as acral melanoma.
In early stages, ALM often appears as a dark brown or black macule with variegated colour, and can be nodular and ulcerated in advanced cases. ALM is slow-growing, and can take months to years to become invasive, ie, to grow beyond the basement membrane of the epidermis where it originates.
Acral lentiginous melanoma (ALM) is the least common subtype of melanoma diagnosed overall, accounting for 2–3% of melanoma diagnoses.
However, ALM is the most common subtype of melanoma in darker skinned populations, accounting for 40–60% of melanoma diagnoses in Asian and African-American ethnicities. It is the least common subtype of melanoma in Caucasian populations.
The incidence of ALM increases with age, with the average age of diagnosis being 63 years. Males and females are equally affected. Females tend to be diagnosed earlier than males.
Acral lentiginous melanoma (ALM) usually arises de novo, but there are rare reports of acral melanoma arising from a pre-existing melanocytic naevus.
The cause of ALM is not fully understood. Unlike other subtypes of melanoma, sun exposure does not appear to be a risk factor for its development, however, there are rare case reports demonstrating an ultraviolet signature as in other types of cutaneous melanoma.
Suggested aetiologies of the cause for ALM include:
The pathogenesis for melanoma includes overgrowth of melanocytes, the pigment-producing cells found deep in the epidermis.
In early stages, acral lentiginous melanoma (ALM) presents as a new light to dark brown pigmented macule on the palm, sole, or under a nail that follow the skin ridges. ALM is more commonly seen on the feet, possibly due to higher melanocyte density.
Occasionally, ALM can present as an amelanotic or hypomelanotic lesion. These are difficult to diagnose as they often mimic benign diseases such as warts or calluses.
Subungual melanoma arises from the nail matrix and usually presents as a longitudinal brown or black band in the fingernail or toenail. It may be associated with nail dystrophy. Involvement of the proximal nail fold (Hutchinson’s sign) is considered a clue to the diagnosis.
Suspicious features for invasive melanoma:
Clinical features do not vary significantly between skin types. It may be more difficult to visualise naevus structure on dermoscopy in darker skin types, appearing as a more homogenous colour.
Complications of untreated disease:
Complications of surgical management:
The diagnosis is often made on clinical history and presentation, supported by dermoscopy.
The following features are seen on dermoscopy for acral lentiginous melanoma (ALM):
Definitive diagnosis is made with histopathology after excision or biopsy of the lesion. Staging is conducted as for any other cutaneous melanoma, with histopathological features such as Breslow depth, ulceration, and sentinel lymph node status.
Histological features of ALM include an asymmetrical proliferation of melanocytes at the dermoepidermal junction.
The differential diagnosis for acral lentiginous melanoma is broad and includes the following:
Of note, pigmented actinic keratoses and seborrhoeic keratoses do not occur on acral surfaces.
Amelanocytic or hypomelanocytic lesions may mimic benign diseases such as warts, calluses, or benign tumours such as poromas.
The mainstay of treatment for acral lentiginous melanoma (ALM) is wide local excision. Further treatment depends mainly on the Breslow thickness of the lesion.
After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, are:
A skin graft or a flap may be needed to close the wound, or in some cases, partial amputation of a digit.
If further treatment is required following excision, this may involve radiotherapy or immunotherapy.
Acral lentiginous melanoma appears to respond less well to combined ipilimumab-nivolumab (IPI-NIVO; two immune checkpoint inhibitors) than other melanomas.
While there are no known preventative strategies, regular skin checks and general sun protection are recommended. Any new lesions noted on the palms, soles, or under the nails should be reviewed by a medical professional.
Compared with cutaneous melanoma, most studies suggest that acral lentiginous melanoma has a poorer prognosis, with diagnosis often occurring at a more advanced clinical stage. It is unclear if this is solely due to delay in ALM detection due to the difficulty in monitoring such sites (eg, soles of the feet), or is also a consequence of genetic and biological differences that promote tumour aggressiveness.
The outcome of ALM depends primarily on Breslow thickness of the lesion and staging, including sentinel lymph node involvement. Other factors that may influence prognosis include age and gender.
An AI summary will appear based on your search term using data from all of the topic pages across the entire DermNet site.
Show more
All DermNet content is researched and written by medical professionals and approved by dermatologists
